The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

DNA Repair Drugs: Focus on PARP Inhibitors, 2016-2026

  • Lowest Price Guaranteed From USD 2,349

  • Published
    May 2016

  • Pages
    284

  • View Count
    769

Example Insights

  1. Overall, we have identified 11 unique PARP inhibitors under clinical/preclinical development; of these, eight (73%) are being developed for oncological indications, two (18%) are under development for stroke and one (9%) is being developed for smoke inhalation injury and primary graft dysfunction.
  2. Four drugs are in late phase (phase III) of development; veliparib (AbbVie), talazoparib (Medivation), niraparib (Tesaro) and rucaparib (Clovis Oncology).
  3. Myriad Genetics and Foundation Medicine have emerged as the major diagnostic developers to actively join hands with PARP inhibitor developers. A companion diagnostic kit called BRACAnalysis CDx®, developed by Myriad Genetics, has been approved to be used with olaparib to detect mutations in the BRCA genes.
  4. We anticipate the PARP inhibitors market to grow aggressively at a healthy annual growth rate of 42% between 2016 and 2026. In the longer term, we expect the market to continue to rise steadily with high adoption rates of marketed drugs and approval of new drugs and indications.
  5. The overall opportunity will certainly face credible competition from several other classes of DNA repair inhibitors that are currently under development. Some prominent examples include APE inhibitors, nucleotide excision repair (NER) pathway inhibitors, O(6)-methylguanine-DNA methyltransferase (MGMT) inhibitors, DNA-protein kinase (DNA-PK) inhibitors, histone deacetylase (HDAC) inhibitors, cyclin dependent kinase (CDK) inhibitors and checkpoint kinase (CHK1) inhibitors.

Overview

DNA is the repository of genetic information in all living cells. Genomic integrity and stability are amongst the key considerations for effective and coordinated biological function. However, DNA is not inert. Cells are continuously exposed to several endogenous and exogenous insults that often cause DNA damage. Despite its role in cellular signalling, ROS, a by-product of mitochondrial respiration, is known to cause severe oxidative DNA damage. Lesions in genomic DNA may also be caused by hydrolysis (deamination, depurination and depyrimidination) and alkylation (6-O-methylguanine) brought about other endogenous insults.Additionally, normal cellular processes, such as replication, are also prone to error. Such erroneous processes often result in the incorporation of incorrect nucleotides leading to formation of lesions in the genome. Exogenous sources of damage may be physical (UV light, ionizing radiations) or chemical (chemotherapeutic drugs, industrial chemicals, cigarette smoke). Overall, it is estimated that every cell experiences up to 105 spontaneous or induced DNA lesions per day.

To detect and correct spontaneous and induced DNA damage, and maintain the integrity and stability of the genome, cells have evolved complex and robust DNA repair mechanisms. The DDR network is a specialized network of proteins and enzymes that is actively engaged in the identification and rectification of lesions and breaks in DNA. Complex organisms have multiple DNA repair pathways, namely the direct repair pathway, excision repair pathways (BER, NER and mismatch repair), and the indirect pathway (HRR and NHEJ). In case one pathway is compromised or rendered dysfunctional, alternate repair pathways are activated to maintain genomic integrity.

Tumor cells that are deficient of a particular repair pathway make optimum use of alternate repair pathways. Such cells up-regulate the expression of certain repair proteins, thereby conferring resistance to therapies that involve DNA damage. Therefore, inhibitors of such compensatory repair pathways have the potential to sensitize cancer cells to DNA damaging agents and associated forms of therapy. The mechanism of action of these drugs relies on the principle of synthetic lethality. PARP inhibitors are an emerging class of drugs that inhibit the BER pathway and lead to the selective elimination of certain types of cancer cells. Normal cells with functional repair pathways remain unaffected by this class of chemotherapeutic drugs.

Currently, only one PARP inhibitor, LynparzaTM (olaparib), is commercially available. Four other PARP inhibitors are being tested in phase III of development for several oncological indications; in addition, molecules are also being developed for non-oncological indications such as smoke inhalation injury and stroke.

 

Scope of the Report

The ‘DNA Repair Drugs: Focus on PARP Inhibitors, 2016-2026’ report is an elaborate study of drugs targeting DNA damage and repair systems, particularly, the enzyme PARP. DNA, the repository of genetic information, is susceptible to damage caused by several environmental and synthetic agents. DNA damage leads to the incorporation of defects and aberrations in the genome that often result in functional mutations. When these mutations occur in genes coding for vital proteins and/or enzymes, it leads to the development of genetic diseases. However, our biological system is equipped with a robust repair mechanism capable of correcting damaged DNA sequences. PARP inhibitors and other similar therapeutics are designed to augment the body’s innate DNA repair mechanism and aid in the treatment of diseases associated with genetic aberrations. So far, this emerging class of drugs has only been evaluated across a niche population segment. This has led to increased efforts in the development of therapeutics targeting cells that harbor defects in their repair systems. There are several targets, other than PARP, that are also under clinical evaluation.

The PARP inhibitors market consists of a thin but promising pipeline of products targeting various indications. Since its serendipitous discovery, the developmental history of these candidate therapeutics has been full of ups and downs. The recalling of the late stage molecule, iniparib, and the termination of several other candidate therapeutics significantly impacted the growth of this segment of the industry. However, it has picked up pace after the commercialization of LynparzaTM (olaparib), the only marketed PARP inhibitor till date. It is important to highlight the role of companion diagnostics, which have significantly contributed to growth in this segment. These molecular tools enabled therapy developers to accurately identify eligible patient groups. Encouraging clinical results demonstrating prolonged PFS and overall survival rates have also accelerated the progress of this drug class.

One of the key objectives of this study was to review and quantify the opportunities laid by the academia/industry players involved in this space. Considering the success of olaparib and clinical data from other active late stage development programs, we have presented an opinion on the anticipated success of PARP inhibitors. Amongst other elements, the report elaborates upon the following key areas:

  • The current state of the market with respect to key players, developmental status of pipeline products (both clinical/preclinical) and target indications
  • The role of innovative companion diagnostics that have contributed significantly in the development of PARP inhibitors
  • An overview of the competitive landscape, elaborating upon other drug classes that explicitly use the DNA repair system as a therapeutic tool
  • An in-depth analysis of all peer-reviewed literature that is available on the key late stage molecules, published in the past few years
  • Development and sales potential of PARP inhibitors based on target consumer segments, likely adoption rate and expected pricing

The analysis in the report is backed by a deep understanding of key drivers behind the market’s growth. With an intent to add comprehensiveness to the market projections, we have provided three market forecast scenarios; the base, optimistic and conservative scenarios represent the likely trends of the future evolution of the market. All actual figures have been sourced and analyzed from publicly available information. The financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  presents an executive summary of the report. It offers a high level view on where the PARP inhibitors market is headed in the coming few years. 

Chapter 3  provides a general introduction to DNA damage and repair. In this section, we have comprehensively discussed DNA damage, providing information on the various types of damages that occur and their causative agents. The chapter also provides information on DNA repair systems and associated biological pathways that are activated during DNA repair. Additionally, it includes a summary of the key clinical findings related to DNA damage and repair that culminated in the development of PARP inhibitors and other similar therapies.

Chapter 4  provides an introduction to PARP inhibitors. It includes information on the classification, anatomical layout and therapeutic potential of PARP inhibitors. The chapter provides a detailed account on the mechanism supporting PARP inhibitors as chemo- and radiosensitizers and their evaluation as combination therapies for oncological indications.

Chapter 5  outlines the evolutionary journey of PARP inhibitors in the current pharmaceutical space. The chapter features a case study on iniparib, the recalled PARP inhibitor; it provides details related to its clinical trial design, key clinical endpoints, key clinical findings, associated side effects and structural features. Additionally, the chapter also talks about other PARP inhibitor programs that were terminated/suspended during clinical development due to various technical reasons.

Chapter 6  provides an overview of the market landscape of PARP inhibitors. This chapter includes information on all the PARP inhibitors that we identified during our research, providing details such as target indications, type of study (combination/monotherapy/maintenance), sub-segment of patients targeted (frontline/pre-treated), phase of development and the active developers engaged in this space.

Chapter 7  contains detailed drug profiles of late stage (phase III) candidate molecules in the PARP inhibitor market. Each drug profile covers information such as mechanism of action, history of development, clinical trial status and assessment of clinical trial endpoints, clinical trial results, manufacturing and a brief overview of the developer company. 

Chapter 8  provides a comprehensive view on the market forecast measuring the opportunity over the coming ten years (2016-2026). We have provided the key assumptions, forecast methodology and patient population of the target indications. In addition, we have separately highlighted the contribution of the approved and phase III PARP inhibitors.

Chapter 9  presents a detailed publication analysis of all peer-reviewed, published literature available on the clinical development of late stage PARP inhibitors in the past few years. The chapter presents a robust analysis showcasing the active drugs, evolving trend of publications, focused clinical endpoints and therapeutic areas across the published data. 

Chapter 10  provides an insight on the competitive landscape of PARP inhibitors. In this chapter, we have provided a glimpse of the various drug classes that are likely to compete with this emerging class of therapeutics. The chapter outlines the specific mechanisms of competing drugs/therapies, along with a summary of their clinical pipeline. These include drug classes such as APE1 inhibitors, NER inhibitors, MGMT inhibitors, DNA-PK inhibitors, HDAC inhibitors, CDK inhibitors and CHK1 inhibitors.

Chapter 11  summarizes the overall report. In this chapter, we have provided a list of key takeaways and have expressed our independent opinion based on the research and analysis described in previous chapters.

Chapter 12  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. DNA DAMAGE AND REPAIR SYSTEMS
3.1. Chapter Overview
3.2. DNA Damage
3.3. DNA Damaging Agents
3.3.1. Endogenous DNA Damaging Agents
3.3.2. Exogenous DNA Damaging Agents
3.3.3. Other DNA Damaging Agents
3.4. DNA Damage Response System
3.4.1. Key Components of the DNA Repair System
 
3.5. Types of DNA Repair Systems
3.5.1. Direct Repair
3.5.1.1. Photo Reactivation
3.5.1.2. Alkyl Transferase Mediated Direct DNA Repair
3.5.1.3. AlkB Mediated Direct DNA Repair
3.5.1.4. DNA Ligase Mediated Direct DNA Repair
 
3.5.2. Excision Repair
3.5.2.1. Base Excision Repair (BER)
3.5.2.1.1. BER Pathway: Key Enzymes
3.5.2.1.1.1. DNA glycosylases: Initiators of the Repair Process
3.5.2.1.1.2. AP Endonucleases
3.5.2.1.1.3. Other Enzymes
3.5.2.1.2. Short-Patch Base Excision Repair
3.5.2.1.3. Long Base Excision Repair
3.5.2.2. Nucleotide Excision Repair (NER)
3.5.2.3. Mismatch Repair (MMR)
 
3.5.3. Indirect Repair
3.5.3.1. Homologous Recombination Repair (HRR)
3.5.3.2. Non-Homologous End-Joining Repair (NHEJ)
 
3.6. Defects in DNA Repair: Onset of Disease
 
4. POLY ADP-RIBOSE POLYMERASE INHIBITORS
4.1. Chapter Overview
4.2. PARP Proteins
4.3. Classification of PARP Proteins
4.4. Anatomical Layout of PARP Proteins
4.5. Applications of PARP Proteins
4.6. Therapeutic Potential of PARP Inhibition
4.6.1. Mechanism of Action: Synthetic Lethality
4.6.2. Mechanism of Action: PARP Trapping
4.7. Genetic Mutations and Susceptibility to PARP Inhibition
4.8. BRCAness and PARP Inhibitor Sensitivity
4.9. Key Clinical Findings
4.10. PARP Inhibitors as Chemosynthesizers and Radiosensitizers
 
5. HISTORY OF DEVELOPMENT
5.1. Chapter Overview
5.2. Discovery of PARP Inhibitors
5.3. Pioneering Research on PARP Inhibitors
5.4. Early Failure of PARP Inhibitors
5.5. Case Study: Iniparib
5.5.1. Iniparib: Clinical Development Plan
5.5.2. Iniparib: Clinical Trial Endpoints
5.5.3. Iniparib: Key Clinical Findings
5.5.4. Iniparib: Reasons for Failure
 
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. PARP Inhibitors: Current Market Landscape
6.3. PARP Inhibitors: Development Pipeline
6.4. PARP Inhibitors: Oncological Indications Emerge as the Most Targeted Therapeutics Area
6.5. PARP Inhibitors: An Evolving Market
6.6. PARP Inhibitors Pipeline: Ovarian and Breast Cancer are the Primary Target Indications
6.7. PARP Inhibitors Pipeline: Catering to a Unique and Niche Patient Segment
6.8. PARP Inhibitors Pipeline: Significant Results Driving PARP Inhibitors as Combination Therapy
6.9. PARP Inhibitors Pipeline: Oral Administration Continues to be the Preferred Choice
 
7. DRUG PROFILES
7.1. Chapter Overview
 
7.2. Olaparib (AstraZeneca)
7.2.1. Introduction
7.2.2. History of Development
7.2.3. Dosage Regimen and Pricing
7.2.4. Companion Diagnostic
7.2.5. Historical Sales
7.2.6. Current Development Status
7.2.7. Clinical Trials
7.2.8. Clinical Trial Endpoints
7.2.9. Key Clinical Trial Results
7.2.9.1. Ovarian Cancer
7.2.9.2. Breast Cancer
7.2.9.3. Gastric Cancer
7.2.9.4. Pancreatic Cancer
7.2.9.5. Prostate Cancer
7.2.9.6. Solid Tumors
7.2.10. Key Preclinical Findings
7.2.11. Developer Overview
7.2.12. Collaborations
 
7.3. Veliparib (AbbVie)
7.3.1. Introduction
7.3.2. Current Status of Development
7.3.3. Clinical Trials
7.3.4. Clinical Trial Endpoints
7.3.5. Key Clinical Trial Results
7.3.5.1. Lung Cancer
7.3.5.2. Brain Cancer
7.3.5.3. Liver Cancer
7.3.5.4. Pancreatic Cancer
7.3.5.5. Breast Cancer
7.3.5.6. Ovarian Cancer
7.3.5.7. Prostate Cancer
7.3.5.8. Solid Tumors
7.3.6. Key Preclinical Findings
7.3.7. Developer Overview
7.3.8. Collaborations
 
7.4. Niraparib (Tesaro)
7.4.1. Introduction
7.4.2. Dosage Regimen
7.4.3. Companion Diagnostic
7.4.4. Patents
7.4.5. Current Development Status
7.4.6. Clinical Trials
7.4.7. Clinical Trial Endpoints
7.4.8. Key Clinical Trial Results
7.4.8.1. Solid Tumors
7.4.9. Key Preclinical Findings
7.4.10. Developer Overview
7.4.11. Collaborations
 
7.5. Talazoparib (Medivation)
7.5.1. Introduction
7.5.2. History of Development
7.5.3. Dosage Regimen
7.5.4. Current Status of Development
7.5.5. Clinical Trials
7.5.6. Planned Studies
7.5.7. Clinical Trial Endpoints
7.5.8. Key Clinical Trial Results
7.5.8.1. Metastatic Breast Cancer
7.5.8.2. Solid Tumors
7.5.9. Key Preclinical Findings
7.5.10. Developer Overview
7.5.11. Collaborations
 
7.6. Rucaparib (Clovis Oncology)
7.6.1. Introduction
7.6.2. History of Development
7.6.3. Dosage Regimen
7.6.4. Companion Diagnostics
7.6.5. Patents
7.6.6. Current Status of Development
7.6.7. Clinical Trials
7.6.8. Clinical Trial Endpoints
7.6.9. Key Clinical Trial Results
7.6.9.1. Ovarian Cancer
7.6.9.2. Solid Tumors
7.6.9.3. Pancreatic Cancer
7.6.10. Key Preclinical Findings
7.6.11. Developer Overview
7.6.12. Collaborations
 
8. MARKET FORECAST
8.1. Chapter Overview
8.2. Forecast Methodology
8.3. Overall PARP Inhibitors Market, 2016-2026
 
8.3.1. Olaparib (Lynparza) (AstraZeneca)
8.3.1.1. Target Patient Population
8.3.1.2. Sales Forecast
 
8.3.2. Veliparib (AbbVie)
8.3.2.1. Target Patient Population
8.3.2.2. Sales Forecast
 
8.3.3. Niraparib (Tesaro)
8.3.3.1. Target Patient Population
8.3.3.2. Sales Forecast
 
8.3.4. Talazoparib (Medivation)
8.3.4.1. Target Patient Population
8.3.4.2. Sales Forecast
 
8.3.5. Rucaparib (Clovis Oncology)
8.3.5.1. Target Patient Population
8.3.5.2. Sales Forecast
 
9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. PARP Inhibitors: Overview of Research
9.3. Olaparib Leads the PARP Inhibitors Research Space; Veliparib to Follow
9.4. 2015 Suggests Renewed Interest in This Drug Class
9.5. Combination Therapy Leads the Research Space of PARP Inhibitors
9.6. Phase I Clinical Trial Data is The Most Documented Literature
9.7. Industry and Academia have Both Contributed to the Development of PARP Inhibitors
9.8. Safety: One of the Most Evaluated Clinical Endpoint
9.9. Ovarian Cancer is The Major Focus Area
 
10. COMPETING CLASSES
10.1. Chapter Overview
 
10.2. Direct Approach
10.2.1. APE Inhibitors (BER)
10.2.2. NER Pathway Inhibitors (NER)
10.2.3. MGMT Inhibitors (Direct Repair Pathway)
10.2.4. DNA Protein Kinase Inhibitors (NHEJ; HRR)
 
10.3. Indirect Mechanism
10.3.1. Histone Deacetylase (HDAC) Inhibitors
10.3.2. Cyclin Dependent Kinase (CDK) Inhibitors
10.3.3. CHK1Inhibitors
 
10.4. Other Novel DNA Repair Inhibitors
10.4.1. SINE XPO1 Antagonist
10.4.2. Pyrrolobenzodiazepine Dimers (PBDs)
10.4.3. RAD51 Inhibitors
10.4.4. DNA Binding Antibody Platform
 
11. CONCLUSION
11.1. A Robust DNA Damage Response Network Helps Maintain the Integrity and Stability of DNA
11.2. Targeting DNA Repair has Demonstrated Tremendous Anti-Cancer Potential
11.3. PARP Inhibitors: A Leading Class of DNA Repair Inhibitors
11.4. A Thin Therapeutic Pipeline Targeting a Niche Population Across Various Cancer Indications
11.5. Companion Diagnostics Aid in the Identification of the Correct Target Population
11.6. Significant Opportunity Amongst Targeted Inhibitors Highlights A Promising Market Ahead
 
12. APPENDIX I: TABULATED DATA
 
13. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Types of DNA Damage
Figure 3.2  DNA Damage: Types of Causative Agents
Figure 3.3 Types of DNA Damage and Repair
Figure 3.4 DNA Damage Response System
Figure 3.5  Types of DNA Repair Systems
Figure 3.6  Base Excision Repair Pathway
Figure 3.7 Nucleotide Excision Repair Pathway
Figure 3.8  Mismatch Repair Pathway
Figure 3.9  Homologous Recombination Repair Pathway
Figure 3.10 Non-Homologous End-Joining Repair
Figure 3.11  Genetic Disorders Caused due to Defects in DNA Repair Pathways
Figure 4.1  PARP Proteins: Mechanism of Action
Figure 4.2  Family Tree of PARP Proteins
Figure 4.3  Structure of PARP-1 and PARP-2
Figure 4.4  Functions of PARP Proteins
Figure 4.5  Mutated Tumors Cells and PARP Inhibition
Figure 4.6  Mechanism of Action: PARP Trapping
Figure 4.7  Systematic Natural DNA Repair vs PARP Inhibition
Figure 6.1  PARP Inhibitors Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical)
Figure 6.2  PARP Inhibitors Pipeline: Distribution by Target Therapeutic Area
Figure 6.3  PARP Inhibitors Pipeline: Distribution by Patient Segment
Figure 6.4  PARP Inhibitors Pipeline: Distribution by Type of Study
Figure 6.5  PARP Inhibitors Pipeline: Distribution by Route of Administration
Figure 7.1  BRACAnalysisCDx Diagnostic Kit: Historical Timeline
Figure 7.2 BRACAnalysisCDx Diagnostic Kit: Working Process
Figure 7.3 AstraZeneca: Revenues, 2009-2015 (USD Billion)
Figure 7.4 AbbVie: Revenues, 2010-2015 (USD Billion)
Figure 7.5 Talazoparib: Unique Features
Figure 7.6 Talazoparib: Planned Studies
Figure 7.7 Rucaparib: Development Timeline
Figure 8.1  Overall PARP Inhibitors Market (USD Million), 2016-2026
Figure 8.2  Olaparib Sales Forecast: Base Scenario (USD Million)
Figure 8.3  Veliparib Sales Forecast: Base Scenario (USD Million)
Figure 8.4  Niraparib Sales Forecast: Base Scenario (USD Million)
Figure 8.5  Talazoparib Sales Forecast: Base Scenario (USD Million)
Figure 8.6  Rucaparib Sales Forecast: Base Scenario (USD Million)
Figure 9.1  PARP Inhibitors Publications: Distribution by Focus Drug
Figure 9.2  PARP Inhibitors Publications: Distribution by Year of Publication
Figure 9.3  PARP Inhibitors Publications: Distribution by Study Type
Figure 9.4  PARP Inhibitors Publications: Distribution by Focus Drug and Study Type
Figure 9.5  PARP Inhibitors Publications: Distribution by Phase of Development
Figure 9.6  PARP Inhibitors Publications: Distribution by Focus Drug and Phase of Development
Figure 9.7  PARP Inhibitors Publications: Distribution by Type of Sponsor
Figure 9.8 PARP Inhibitors Publications: Distribution by Focus Drug and Type of Sponsor
Figure 9.9  PARP Inhibitors Publications: Distribution by Evaluable Clinical Endpoints
Figure 9.10  PARP Inhibitors Publications: Distribution by Focus Drug and Evaluable Clinical Endpoints
Figure 9.11  PARP Inhibitors Publications: Distribution by Therapeutic Area
Figure 9.12  PARP Inhibitors Publications: Distribution by Drug and Focus Therapeutic Area
Figure 10.1  Classification of HDACs
Figure 10.2  Cell Cycle Regulation
Figure 11.1  PARP Inhibitors And Companion Diagnostics: Collaborations
Figure 11.2 Overall PARP Inhibitors Market Summary (USD Million): 2016, 2021, 2026

List of Tables

Table 3.1 Components of DNA Repair System
Table 3.2  Difference between the HR and NHEJ Pathway
Table 4.1  DNA Damaging Agents Used in Cancer Therapy
Table 5.1  List of Terminated/Withdrawn PARP Inhibitors
Table 5.2  Iniparib: Clinical Trials
Table 5.3  Iniparib: Phase III Clinical Trial Endpoints
Table 5.4  Iniparib: Phase II Clinical Trial Endpoints-1
Table 5.5  Iniparib: Phase II Clinical Trial Endpoints-2
Table 6.1  PARP Inhibitors: Clinical/Preclinical Pipeline
Table 6.2  PARP Inhibitors: Clinical Development Scenario
Table 7.1  Olaparib: Current Status of Development
Table 7.2 Olaparib: Industry Sponsored Clinical Trials
Table 7.3 Olaparib: Non-Industry Sponsored Clinical Trials
Table 7.4 Olaparib: Phase III Clinical Trial Endpoints-1
Table 7.5 Olaparib: Phase III Clinical Trial Endpoints-2
Table 7.6 Company Overview: AstraZeneca
Table 7.7 Veliparib: Current Status of Development
Table 7.8 Veliparib: Industry Sponsored Clinical Trials
Table 7.9 Veliparib: Non-Industry Sponsored Clinical Trials
Table 7.10 Veliparib: Phase III Clinical Trial Endpoints
Table 7.11 Company Overview: AbbVie
Table 7.12  Niraparib: Patent Portfolio
Table7.13 Niraparib: Current Status of Development
Table7.14 Niraparib: Clinical Trials
Table 7.15 Niraparib: Phase III Clinical Trial Endpoints
Table 7.16 Niraparib: Phase II Clinical Trial Endpoints
Table 7.17 Niraparib: Phase I Clinical Endpoints
Table 7.18  Company Overview: Tesaro
Table7.19 Talazoparib: Current Status of Development
Table 7.20 Talazoparib: Industry Sponsored Clinical Trials
Table 7.21 Talazoparib: Non-Industry Clinical Trials
Table 7.22 Talazoparib: Phase II Clinical Trial Endpoints
Table 7.23 Talazoparib: Phase I Clinical Trial Endpoints
Table 7.24 Company Overview: Medivation
Table 7.25 Rucaparib: Current Status of Development
Table 7.26 Rucaparib: Clinical Trials
Table 7.27 Rucaparib: Phase II Clinical Trial Endpoints
Table 7.28 Rucaparib: Phase I Clinical Trial Endpoints
Table 7.29  Company Overview: Clovis Oncology
Table 8.1 PARP Inhibitors: Market Potential for Candidates
Table 8.2  Olaparib: Target Patient Population
Table 8.3  Rucaparib: Target Patient Population
Table 8.4  Niraparib: Target Patient Population
Table 8.5  Veliparib: Target Patient Population
Table 8.6  Talazoparib: Target Patient Population
Table 9.1  PARP Inhibitors Publications
Table 10.1 APE1 Inhibitors Pipeline
Table 10.2  NER Inhibitors Pipeline
Table 10.3  DNA PK Inhibitors Pipeline
Table 10.4  DNA Repair: Effect of Histone Modifications
Table 10.5  HDAC Inhibitors Pipeline
Table 10.6  CDKs: Functions and Emerging Areas of Research
Table 10.7  CDK Inhibitors Pipeline
Table 10.8  CHK1 Inhibitors: Clinical Pipeline
Table 10.9  Other Novel DNA Repair Inhibitors
Table 10.10  Selinexor: Clinical Pipeline
Table 12.1 PARP Inhibitors Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical) 
Table 12.2  PARP Inhibitors Pipeline: Distribution by Target Therapeutic Area
Table 12.3  PARP Inhibitors Pipeline: Distribution by Patient Segment
Table 12.4  PARP Inhibitors Pipeline: Distribution by Type of Study
Table 12.5  PARP Inhibitors Pipeline: Distribution by Route of Administration
Table 12.6  AstraZeneca: Revenues, 2009-2015 (USD Billion)
Table 12.7  AbbVie: Revenues, 2010-2015 (USD Billion)
Table 12.8  Overall PARP Market: Conservative Scenario (USD Million), 2016 – 2026
Table 12.9  Overall PARP Market: Base Scenario (USD Million), 2016 – 2026
Table 12.10 Overall PARP Market: Optimistic Scenario (USD Million), 2016 – 2026
Table 12.11  Olaparib Sales Forecast: Conservative Scenario (USD Million)
Table 12.12 Olaparib Sales Forecast: Base Scenario (USD Million)
Table 12.13  Olaparib Sales Forecast: Optimistic Scenario (USD Million)
Table 12.14  Veliparib Sales Forecast: Conservative Scenario (USD Million)
Table 12.15  Veliparib Sales Forecast: Base Scenario (USD Million)
Table 12.16  Veliparib Sales Forecast: Optimistic Scenario (USD Million)
Table 12.17  Niraparib Sales Forecast: Conservative Scenario (USD Million)
Table 12.18  Niraparib Sales Forecast: Base Scenario (USD Million)
Table 12.19  Niraparib Sales Forecast: Optimistic Scenario (USD Million)
Table 12.20  Talazoparib Sales Forecast: Conservative Scenario (USD Million)
Table 12.21  Talazoparib Sales Forecast: Base Scenario (USD Million)
Table 12.22  Talazoparib Sales Forecast: Optimistic Scenario (USD Million)
Table 12.23 Rucaparib Sales Forecast: Conservative Scenario (USD Million)
Table 12.24  Rucaparib Sales Forecast: Base Scenario (USD Million)
Table 12.25  Rucaparib Sales Forecast: Optimistic Scenario (USD Million)
Table 12.26  PARP Inhibitors Publications: Distribution by Focus Drug
Table 12.27  PARP Inhibitors Publications: Distribution by Year of Publication
Table 12.28  PARP Inhibitors Publications: Distribution by Study Type
Table 12.29  PARP Inhibitors Publications: Distribution by Focus Drug and Study Type
Table 12.30  PARP Inhibitors Publications: Distribution by Phase of Development  
Table 12.31  PARP Inhibitors Publications: Distribution by Focus Drug and Phase of Development
Table 12.32  PARP Inhibitors Publications: Distribution by Type of Sponsor
Table 12.33  PARP Inhibitors Publications: Distribution by Focus Drug and Type of Sponsor
Table 12.34  PARP Inhibitors Publications: Distribution by Evaluable Clinical Endpoints
Table 12.35  PARP Inhibitors Publications: Distribution by Focus Drug and Evaluable Clinical Endpoints
Table 12.36  PARP Inhibitors Publications: Distribution by Therapeutic Area  
Table 12.37  PARP Inhibitors Publications: Distribution by Focus Drug and Focus Therapeutics Area
Table 12.38  Overall PARP Inhibitors Market Summary (USD Million): 2016, 2021, 2026

Listed Companies

The following companies have been mentioned in the report.

  1. 4SC AG
  2. AbbVie
  3. Agouron Pharmaceuticals
  4. Almac Group
  5. Array BioPharma
  6. Astellas
  7. Astex Pharmaceuticals
  8. AstraZeneca
  9. BeiGene
  10. BioMarin Pharmaceuticals
  11. Bristol Myers Squibb
  12. BiPar Sciences
  13. Celgene
  14. Cephalon
  15. Checkpoint Therapeutics
  16. ChemPartners (Service unit of ShangPharma)
  17. Clovis Oncology
  18. Cyclacel Pharmaceuticals
  19. Cyteir Therapeutics
  20. Eisai
  21. Eli Lilly
  22. Eternity Biosciences
  23. Foundation Medicine
  24. Genentech
  25. GlaxoSmithKline
  26. HD Biosciences Corporation
  27. Inotek Pharmaceuticals
  28. Italfarmaco
  29. Jeil Pharmaceutical
  30. Jiangsu Hengrui Medicine
  31. Johnson & Johnson
  32. Karyopharm Therapeutics
  33. KuDOS Pharmaceuticals
  34. LEAD Therapeutics
  35. MedImmune
  36. Medivation
  37. MEI Pharma
  38. Merck
  39. Merck KGaA
  40. MT Pharma
  41. Myriad Genetics
  42. NeRX Biosciences
  43. Novartis
  44. Oncothyreon
  45. Onxeo
  46. Patrys
  47. Pfizer
  48. Pharmacyclis
  49. PharmaMar
  50. Pharmion Corporation
  51. Pivot Pharmaceuticals
  52. Quintiles
  53. Radikal Therapeutics
  54. Sanofi
  55. Sentinel Oncology
  56. Serometrix
  57. Sunesis Pharmaceuticals
  58. Syndax Pharmaceuticals
  59. Tesaro
  60. Tiziana Life Sciences
  61. Tolero Pharmaceuticals
  62. Tracon Pharmaceuticals
  63. Vernalis

The following organizations have been mentioned in the report

  1. American Association for Cancer Research
  2. ARCAGY/ GINECO GROUP
  3. American Society of Clinical Oncology
  4. Ascopharm Groupe Novasco
  5. Beijing Cancer Hospital
  6. Beth Israel Deaconess Medical Center
  7. Breast International Group
  8. Br.E.A.S.T.-Data Center & Operational Office Institut Jules Bordet
  9. Breast Cancer Research Foundation
  10. British Columbia Cancer Agency
  11. Cambridge University Hospitals NHS Foundation Trust
  12. Cancer Research UK
  13. Cedars-Sinai Medical Center
  14. Christie Hospital NHS Foundation Trust
  15. Cooperative Ovarian Cancer Group for Immunotherapy
  16. Dana-Farber Cancer Institute
  17. European Cancer Congress
  18. Eastern Cooperative Oncology Group
  19. European Network of Gynaecological Oncology Trial Groups
  20. European Organization For Research And Treatment
  21. European Society of Gynecological Oncology
  22. European Society for Medical Oncology
  23. National Health Service
  24. European Cancer Observatory
  25. FORCE: Facing Our Risk of Cancer Empowered
  26. International Federation of Gynecology and Obstetrics
  27. Frontier Science & Technology Research Foundation
  28. Gynecologic Cancer InterGroup
  29. Georgetown University
  30. German Breast Group
  31. Gynecologic Oncology Group
  32. Grupo Espanol de Investigacion del Cancer de Mama
  33. Gustave Roussy, Cancer Campus, Grand Paris
  34. Hoosier Cancer Research Network
  35. Institute of Cancer Research, UK
  36. Istituti Ospitalieri di Cremona
  37. Istituto Di Ricerche Farmacologiche
  38. Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
  39. Italian Sarcoma Group
  40. Jiangsu Hengrui Medicine
  41. Jonsson Comprehensive Cancer Center
  42. M.D. Anderson Cancer Center
  43. Massachusetts General Hospital
  44. Medical School of Newcastle University
  45. Memorial Sloan Kettering Cancer Center
  46. National Breast Cancer Coalition
  47. National Cancer Institute
  48. National Crime Information Center
  49. New Mexico Cancer Care Alliance
  50. Newcastle University
  51. The National Institute for Health and Care Excellence
  52. Northern Institute of Cancer Research
  53. National Institutes of Health
  54. National Institutes of Health Clinical Center
  55. NSABP Foundation
  56. Prostate Cancer Clinical Trials Consortium
  57. QuantumLeap Healthcare Collaborative
  58. Radiation Therapy Oncology Group
  59. Royal Marsden NHS Foundation Trust
  60. Samsung Medical Centre
  61. SARC
  62. Sheba Medical Center
  63. Sidney Kimmel Comprehensive Cancer Center
  64. SOLTI Breast Cancer Research Group
  65. Spanish Lung Cancer Group
  66. St. Jude Children's Research Hospital
  67. Stanford University
  68. Swedish Medical Center
  69. The Netherlands Cancer Institute
  70. Third Military Medical University
  71. Translational Research in Oncology
  72. UNC Lineberger Comprehensive Cancer
  73. UNICANCER
  74. University College, London
  75. University Health Network
  76. University of California, San Francisco
  77. University of Colorado
  78. University of Michigan Cancer Center
  79. University of Sheffield
  80. University of Toronto
  81. University of Washington
  82. US Department of Health and Human Services
  83. US Department of Labor
  84. US Department of Treasury
  85. US Oncology Research
  86. Vanderbilt-Ingram Cancer Center
  87. Vejle Hospital
  88. Velindre NHS Trust
  89. Yale University
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com